Phase I dose escalation and pharmacokinetic study of SSR97225 administered as a 1 hour IV infusion D1 every 3 weeks (arm A) or administered as a 1hour IV infusion D1, D8, D15 every 3 weeks (arm B) in patients with refractory solid tumors

Trial Profile

Phase I dose escalation and pharmacokinetic study of SSR97225 administered as a 1 hour IV infusion D1 every 3 weeks (arm A) or administered as a 1hour IV infusion D1, D8, D15 every 3 weeks (arm B) in patients with refractory solid tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2009

At a glance

  • Drugs SSR 97225 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 01 May 2009 Planned number of patients changed from 48 to 6 as reported by ClinicalTrials.gov.
    • 01 May 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 16 Oct 2008 Actual start date changed from Aug 2009 to Aug 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top